帕尼单抗联合曲氟尿苷替匹嘧啶作为抗表皮生长因子受体再挑战治疗用于难治性RAS野生型转移性结直肠癌:一项2期随机临床试验
这项在意大利7个中心开展的2期随机临床试验纳入62例对一线化疗联合抗EGFR单抗有效且二线治疗期间无抗EGFR药物间期≥4个月的难治性RAS野生型转移性结直肠癌患者,比较帕尼单抗联合曲氟尿苷替匹嘧啶与单用曲氟尿苷替匹嘧啶的疗效。结果显示联合组中位无进展生存期4.0个月 vs 单药组2.5个月(HR 0.48,95%CI 0.28-0.82,P=0.007),达到主要终点。
要点
- 帕尼单抗联合曲氟尿苷替匹嘧啶较单药显著改善难治性RAS野生型转移性结直肠癌的无进展生存期。
- 治疗前血浆RAS/BRAF野生型ctDNA可识别从联合治疗中获得持久临床获益的患者。
- 基线血浆RAS/BRAF野生型ctDNA且肿瘤KRAS、NRAS、BRAFV600E、EGFR、ERBB2、MAP2K1、PIK3CA均野生型的15例患者中位无进展生存期6.4个月。
核心结论
- 在这项随机临床试验中,帕尼单抗联合标准化疗曲氟尿苷替匹嘧啶三线治疗难治性RAS野生型转移性结直肠癌患者,较单用曲氟尿苷替匹嘧啶改善了无进展生存期。
- 研究结果支持液体活检指导的抗EGFR再挑战治疗用于难治性RAS野生型转移性结直肠癌的临床效用。
研究设计与样本
- 这项2期随机临床试验于2019年6月至2022年4月在7个意大利中心开展。
- 纳入对一线化疗联合抗EGFR单抗获得部分或完全缓解、且二线治疗期间无抗EGFR药物间期≥4个月的难治性RAS野生型转移性结直肠癌患者。
- 共纳入62例患者,按1:1随机接受帕尼单抗联合曲氟尿苷替匹嘧啶或单用曲氟尿苷替匹嘧啶。
- 主要终点为无进展生存期。
- 对部分患者进行了循环肿瘤DNA扩展序列变异分析。
主要发现
- 帕尼单抗联合曲氟尿苷替匹嘧啶组31例(男性19例[61.3%],中位年龄65岁[范围39-81岁]),单用曲氟尿苷替匹嘧啶组31例(男性17例[54.8%],中位年龄66岁[范围32-82岁])。
- 联合组中位无进展生存期4.0个月(95%CI 2.8-5.3个月)vs 单药组2.5个月(95%CI 1.4-3.6个月),HR 0.48(95%CI 0.28-0.82),P=0.007。
- 治疗前血浆RAS/BRAF野生型ctDNA患者中,联合组vs单药组6个月无进展生存率38.5% vs 13.0%,12个月无进展生存率15.4% vs 0%。
- 基线血浆RAS/BRAF野生型ctDNA且肿瘤KRAS、NRAS、BRAFV600E、EGFR、ERBB2、MAP2K1、PIK3CA均野生型的23例患者中,15例(65.2%)中位无进展生存期6.4个月(95%CI 3.7-9.2个月)。
- 上述15例患者中,最佳疗效为部分缓解2例(13.3%)、疾病稳定11例(73.3%)、疾病进展2例(13.3%)。
关键数值与推荐
- 主要终点无进展生存期达到:联合组中位4.0个月(95%CI 2.8-5.3个月)vs 单药组2.5个月(95%CI 1.4-3.6个月),HR 0.48(95%CI 0.28-0.82),P=0.007。
- 治疗前血浆RAS/BRAF野生型ctDNA患者6个月无进展生存率联合组38.5% vs 单药组13.0%,12个月无进展生存率联合组15.4% vs 单药组0%。
- 基线血浆RAS/BRAF野生型ctDNA且肿瘤KRAS、NRAS、BRAFV600E、EGFR、ERBB2、MAP2K1、PIK3CA均野生型的15例患者中位无进展生存期6.4个月(95%CI 3.7-9.2个月)。
临床怎么用
- 作者认为,研究结果支持液体活检指导的抗EGFR再挑战治疗用于难治性RAS野生型转移性结直肠癌的临床效用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Current third-line therapies for patients with metastatic colorectal cancer (MCRC) have limited efficacy. Rechallenge with epidermal growth factor receptor (EGFR) inhibitors for RAS wild-type (WT) MCRC may be valuable for these patients. OBJECTIVE: To compare the anti-EGFR monoclonal antibody panitumumab plus standard-of-care trifluridine-tipiracil with trifluridine-tipiracil alone as third-line therapy for RAS WT MCRC. DESIGN, SETTING, AND PARTICIPANTS: This phase 2 randomized clinical trial (RCT) was conducted in 7 Italian centers from June 2019 to April 2022. Patients with refractory RAS WT MCRC who had a partial or complete response to first-line chemotherapy plus an anti-EGFR monoclonal antibody and an anti-EGFR drug-free interval of 4 or more months during second-line therapy were included. INTERVENTIONS: Patients were randomized 1:1 to receive panitumumab plus trifluridine-tipiracil or trifluridine-tipiracil alone. MAIN OUTCOMES AND MEASURES: The primary end point was progression-free survival (PFS). Circulating tumor DNA (ctDNA) extended sequence variation analysis was performed in a subgroup of patients. RESULTS: Of 62 included patients, 31 received panitumumab plus trifluridine-tipiracil (19 [61.3%] male; median age, 65 years [range, 39-81 years]) and 31 received trifluridine-tipiracil alone (17 [54.8%] male; median age, 66 years [range, 32-82 years]). The primary end point was met. Median PFS was 4.0 months (95% CI, 2.8-5.3 months) in the panitumumab plus trifluridine-tipiracil arm vs 2.5 months (95% CI, 1.4-3.6 months) in the trifluridine-tipiracil only (hazard ratio [HR], 0.48; 95% CI, 0.28-0.82; P = .007). Pretreatment plasma RAS/BRAF WT ctDNA identified patients obtaining prolonged clinical benefit with panitumumab plus trifluridine-tipiracil compared with trifluridine-tipiracil, with PFS rates at 6 months of 38.5% vs 13.0% and at 12 months of 15.4% vs 0%. A ctDNA liquid-biopsy extended mutation analysis by FoundationOne Liquid CDx (profiling 324 genes) was performed in a subgroup of patients with baseline plasma RAS/BRAF WT ctDNA; in 15 of 23 patients (65.2%) whose tumors were WT for KRAS, NRAS, BRAFV600E, EGFR, ERBB2, MAP2K1, and PIK3CA, median PFS was 6.4 months (95% CI, 3.7-9.2 months). Within this group of 15 patients, 2 (13.3%) had partial response, 11 (73.3%) had stable disease, and 2 (13.3%) had disease progression as best response. CONCLUSIONS AND RELEVANCE: In this RCT, third-line treatment with the anti-EGFR monoclonal antibody panitumumab plus the standard-of-care trifluridine-tipiracil resulted in improved PFS compared with treatment with trifluridine-tipiracil alone among patients with refractory RAS WT MCRC. The findings support the clinical utility of liquid biopsy-guided anti-EGFR rechallenge therapy for refractory RAS WT MCRC. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05468892.
引用
- Napolitano S, De Falco V, Martini G, et al. Panitumumab Plus Trifluridine-Tipiracil as Anti-Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2023. PMID: 37200022. doi:10.1001/jamaoncol.2023.0655
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。